Part I of this review discussed pharmacotherapy of primary pulmonary hypertension (PHT). Part II describes the value and limitations of oxygen and vasodilator therapy of secondary PHT, focusing on patients with PHT associated with selected connective tissue disease and chronic nonthrombotic hypoxic lung disease.
Get full access to this article
View all access options for this article.
References
1.
Grossman W., Braunwald E.: Pulmonary hypertension. In: Heart Disease: A Textbook of Cardiovascular Disease, ed. 4, ed. by Braunwald E.Philadelphia: W. B. Saunders Co, 1992, pp 790—818.
2.
Silver R., Miller K.: Lung involvement in systemic sclerosis. RheumClin North Am16:199-216, 1990.
3.
Young R., Mask G.: Pulmonary vascular changes in scleroderma. Am J Med64:998-1004, 1978.
4.
Naslund MJ, Pearson TA, Ritter JM: A documented episode of pulmonary vasoconstriction in systemic sclerosis. Johns Hopkins Med J148:78-80, 1981.
5.
Rozkovec A., Bernstein R., Atherton RA, et al: Vascular reactivity and pulmonary hypertension in systemic sclerosis . Arthritis Rheum26:1038-1049, 1983 .
6.
Morgan M., Griffiths M., duBois R., et al: Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest99:551-556, 1991.
7.
Yousem SA: Pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol21:467-474, 1990.
8.
Alpert MA, Goldberg S., Singsen BH, et al: Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation68:1182-1193, 1983 .
9.
O'Brien DT, Hill DA, Pepine CJ: Sustained benefit of verapamil in pulmonary hypertension with progressive systemic sclerosis. Am Heart J109:380-382, 1985.
10.
Glikson M., Pollack A., Dresser-Feigin R., et al: Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. Chest98:759-761, 1990.
11.
Fudman E., Kelling D. Jr: Transient effect of nifedipine on pulmonary hypertension of systemic sclerosis . J Rheum12:1191-1192, 1985 .
12.
Ocken S., Reinitz E., Strom J.: Nifedipine treatment for pulmonary hypertension in a patient with systemic sclerosis. Arthritis Rheum26:794-796, 1983.
13.
Ohar D., Polatty C., Robichaud A., et al: The role of vasodilators in patients with progressive systemic sclerosis. Interstitial lung disease and pulmonary hypertension. Chest88:263S-265S, 1985.
14.
Sfikakis P. , Kyriakidis M., Vergos C., et al: Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. Am J Med90:541-546, 1991.
15.
Alpert MA, Pressly TA, Mukerji V., et al: Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol68:1187-1191, 1991.
16.
Richard C., Rocome DL, Lemoine F., et al: Value of captopril in the treatment of systemic arterial and pulmonary hypertension with increased plasma renin and scleroderma. Rev Med Int4:125-129, 1982.
17.
Alpert MA, Pressly TA, Mukerji V., et al: Short and long-term hemodynamic effects of captopril in patients with selected connective tissue diseases. Chest102:1407-1412, 1992.
18.
Niarchos AP , Whitman HH, Goldstein DE, et al: Hemodynamic effects of captopril in pulmonary hypertension of collagen vascular disease. Am Heart J104:834-838, 1982.
19.
Phillipoteau C., Brendt F., Bletry D., et al: Vasodilatory agents in pulmonary hypertension of systemic scleroderma. Rev Mal Respir7:249-254, 1990.
20.
Seibold DR, Molony RR, Tarkevoch D., et al: Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis. J Rheum14:419-424, 1987.
Watkins T.: Effect of various therapies on pulmonary hemodynamics in a patient with pulmonary hypertension due to chronic lung disease. Lancet1:1083-1087, 1983.
23.
Saadjian A. , Philip-Joel F., Levy S., et al: Vascular and cardiac reactivity in pulmonary hypertension due to chronic obstructive lung disease: Assessment with various oxygen concentrations. Eur Resp J67:346-350, 1992.
24.
Stark RD, Finnegan P., Bishop JM: Daily requirements of oxygen to reverse pulmonary hypertension in patients with chronic bronchitis. Br Med J3:724-728, 1972.
25.
Abraham AS, Cole RB, Bishop JM: Reversal of pulmonary hypertension by prolonged oxygen administration to patients with chronic bronchitis. Circ Res23:147-157, 1968.
26.
Hamet A., Kral B., Cernahorsky D.: Comparative effects of oxygen, nifedipine and ketanserin in hypoxic pulmonary hypertension. Cor Vasc25:406-411, 1985.
27.
Ido A., Tsuji T., Shimizu T., et al: Effects of denopamine on hemodynamics and blood gases in secondary pulmonary hypertension. Nippon-Kyobu, Shikkem-Gakrai-Zasshi29:1553-1559, 1991.
28.
Rubin LJ, Peter RH: Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. Am J Cardiol47:116-122, 1981.
29.
Dal Nagare A , Rubin LJ: The effects of hydralazine on exercise capacity in pulmonary hypertension secondary to chronic obstructive pulmonary disease . Am Rev Respir Dis133:384-389, 1986.
30.
Stumpke KO, Schmangler K., Bette L., et al: Persistent hemodynamic and clinical improvement after captopril in patients with pulmonary hypertension. Herz11:217-225, 1986.
31.
Resin CM, Wolf DE, Levy PA, et al: Effects of captopril combined with oxygen therapy at rest and on exercise in patients with chronic bronchitis and pulmonary hypertension . Respiration58:9-14, 1991.
32.
Escudero J. , Navarro J., Padua A., et al: Use of enalapril, an angiotensin-converting enzyme inhibitor in pulmonary artery hypertension. Arch Inst Cardiol Mex56:6-12, 1986.
33.
Saadjian A. , Philip-Joet F., Guintoli A., et al: Effect of nifedipine on pulmonary hemodynamics of 10 patients with COPD and pulmonary hypertension. Eur J Resp Dis67:346-350, 1985.
34.
Dubiel JP, Nikodemowica M., Znudka K., et al: Comparative study of nifedipine on patients with secondary pulmonary hypertension. Kardiol Pol34:279-286, 1991.
35.
Liu Z., Yu RJ: Effects of nifedipine on pulmonary hypertension in patients with chronic obstructive pulmonary disease—a comparison with oxygen administration. Chung Hua Chieh Ho Ho Hsu; Tsa Chih14:146-148, 1991.
36.
Domenighetti GM, Sagline VG: Short and long term hemodynamic effects of oral nifedipine in patients with pulmonary hypertension secondary to COPD and lung fibrosis. Chest102:708-714, 1985.
37.
Garzanti N. , El Allaf D., D'orio V., et al: Effect of sublingual nifedipine on pulmonary hemodynamics in 13 patients with secondary pulmonary hypertension . Acta Cardiol40:207-215, 1985.
38.
Johnson HC, Joski RC, Mekta R., et al: Acute and long term effects of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease. Eur J Respir Dis69:146-151, 1986.
39.
Occhi G., Bifi R., Gemma S., et al: Acute effects of diltiazem in pulmonary hypertension secondary to chronic obstructive pulmonary disease. G Ital Cardiol16:9-13, 1986.
40.
Burger W., Jandl M., Gellert D., et al: Acute and chronic effects of nitrendipine in patients with precapillary pulmonary hypertension due to pulmonary fibrosis. Clin Cardiol19:220-225, 1991.
41.
Jones K., Higenbottam T., Wallwork D.: Pulmonary vasodilatation with prostacyclin in primary and secondary pulmonary hypertension. Chest96:784-789, 1989.
